Biden wishes to spend billions more on COVID-19 efforts at home and abroad. US federal funding agencies haven’t discussed specific funding opportunities based on the administration’s proposals, but it is likely there will be more funding available to biotech R&D on anti-virals, vaccines, diagnostics, etc.
The National Institute of Allergy & Infectious Diseases (NIAID) has just published a Broad Agency Announcement (BAA). This BAA contains four distinct Research Areas: Vaccines, Therapeutics, and In-Vitro Diagnostics for Biodefense, Antimicrobial Resistant Infections and Emerging Infectious Diseases, and Antivirals for Specific RNA Viral Families of Pandemic Potential.
FreeMind can help you apply for these funds or for other non-dilutive grants and contracts. FreeMind will host a webinar about the BAA on February 7, at 1:00 PM EST.
Tyler Merkeley, CARB-X co-founder and program director for ASPR’s Biomedical Advanced Research and Development Authority, describes the drivers and next steps in creating a diverse portfolio Powered by CARB-X, one of the world’s largest public-private partnerships dedicated to accelerating development of innovative antibacterial drugs, diagnostics, and devices.
Website Links
Address
FreeMind Group
6 Liberty Square #2783
Boston, MA 02109